Lipocine Inc.
LPCN
$3.09
-$0.16-4.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 595.09% | -98.77% | 1,514.89% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 595.09% | -98.77% | 1,514.89% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 595.09% | -98.77% | 1,514.89% | -- |
| SG&A Expenses | -26.54% | -40.93% | -28.76% | -23.05% | 0.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.13% | -10.49% | -50.30% | -30.74% | -32.92% |
| Operating Income | -27.77% | 26.98% | -164.86% | 159.59% | 62.65% |
| Income Before Tax | -43.63% | 28.11% | -153.07% | 178.11% | 66.64% |
| Income Tax Expenses | -- | -- | 0.00% | -100.00% | -- |
| Earnings from Continuing Operations | -43.63% | 28.12% | -153.08% | 178.09% | 66.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.63% | 28.12% | -153.08% | 178.09% | 66.64% |
| EBIT | -27.77% | 26.98% | -164.86% | 159.59% | 62.65% |
| EBITDA | -27.65% | 27.28% | -164.21% | 160.38% | 62.73% |
| EPS Basic | -41.89% | 28.23% | -152.75% | 177.61% | 66.99% |
| Normalized Basic EPS | -41.92% | 28.21% | -152.75% | 177.67% | 66.99% |
| EPS Diluted | -33.88% | 28.23% | -152.95% | 172.52% | 65.32% |
| Normalized Diluted EPS | -41.92% | 28.21% | -153.16% | 173.08% | 66.99% |
| Average Basic Shares Outstanding | 1.22% | 0.15% | 0.62% | 0.60% | 1.05% |
| Average Diluted Shares Outstanding | 1.22% | 0.15% | -0.17% | 6.89% | 1.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |